Alzamend Neuro
ALZN
31 hedge funds and large institutions have $4.04M invested in Alzamend Neuro in 2022 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
650% more call options, than puts
Call options by funds: $195K | Put options by funds: $26K
533% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 3
107% more funds holding
Funds holding: 15 → 31 (+16)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
57% less capital invested
Capital invested by funds: $9.41M → $4.04M (-$5.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$66.6K |
| 2 |
HF
HRT Financial
New York
|
+$60.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$59.4K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$56.5K |
| 5 |
Renaissance Technologies
New York
|
+$53.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.61M |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$34.7K |
| 3 |
DFCM
Dark Forest Capital Management
San Juan,
Puerto Rico
|
-$13K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$10.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.45K |
ALZN Hedge Fund Activity: Q4 2022 in Review
31 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2022, worth a combined $4.04M — down 57% from $9.41M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ALZN positions and 3 closed out — a net gain of 16 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $66.6K. The largest seller was Vanguard Group, cutting an estimated $1.61M.
- 31 institutional investors held Alzamend Neuro (ALZN) as of Q4 2022, up from 15 in Q3 2022.
- Funds reported $4.04M of Alzamend Neuro stock for Q4 2022, down 57% quarter-over-quarter.
- 19 funds opened new Alzamend Neuro positions in Q4 2022 and 3 closed out, a net change of +16 holders.
- The largest Alzamend Neuro buyer in Q4 2022 was Virtu Financial, an estimated $66.6K added.
- The largest Alzamend Neuro seller in Q4 2022 was Vanguard Group, an estimated $1.61M sold.
Based on aggregated 13F filings for Q4 2022.